BioSpace News Archive

Protillion Biosciences today announced the completion of an $18 million Series A financing from ARCH Venture Partners and Illumina Ventures.

Lipocine Inc. today announced that it has completed enrollment in its Phase 2 proof-of-concept (“POC”) study evaluating the therapeutic potential of LPCN 1148 for the management of decompensated cirrhosis of various etiologies. Lipocine intends to explore partnering LPCN 1148.

DarioHealth Corp. (NASDAQ: DRIO) (the “Company”), a leader in the global digital therapeutics (DTx) market, announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness of the Company’s musculoskeletal solution, which uses real-time biofeedback and behavior training to reduce back pain.

Ordaōs today announced a joint development agreement to create new therapeutics for two novel targets in Acute Myeloid Leukemia (AML) with Yatiri Bio, a biotechnology company that has developed a proprietary platform that links patient proteomic and clinical data to context-specific ex-vivo model systems to drive efficient drug development and advance personalized medicines.

BioLife Solutions, Inc. (NASDAQ: BLFS) today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on January 9, 2023, in advance of management’s meetings with investors, customers, and partners concurrent with the 41st Annual J.P. Morgan Health Care Conference in San Francisco January 9-12.

UroGen Pharma Ltd. announced that the Phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled.

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).

ICU Medical, (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the J.P. Morgan 41st Annual Healthcare Conference, being held in San Francisco, CA, January 9-12, 2023.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.